Catapult Solutions Group: Redefining Recruiting

Outside recruiters and recruitment is widely accepted as a valuable resource as candidates enter the job market. Bobby Brill sits down with Michael Boyles, VP of Operations at Catapult Federal Services, and Josh Rainier, Human Resources Administrator of Catapult Solutions Group, to discuss what it takes to build a great recruiter and candidate relationship.

Boyles describes the Catapult approach as “old school meets new school.” He explains that while he values technology, the focus should first and always remain on the person and building relationships.

The first is the relationship with the candidate. Recruiters should focus on trust and transparency. Candidates should feel comfortable talking about themselves openly. “Be yourself, be honest with people, tell them up front where the gaps and warts are,” said Boyles. Catapult ensures that candidates don’t feel like they’re just another number in the system. Recruiters lay the foundation of the relationship with their candidates from the jump. “Catapult Solutions focuses on person-to-person contact,” said Boyles.

Rainier, who started recruiting but is now working within HR, understands the daunting task of being in the job market. First and foremost, recruiters need to build rapport with candidates. With empathy, recruiters should remember that this person is making a big life decision. “You need to have a certain amount of information [about the position] to make the decision that could impact your next 5 to 10 years,” said Rainier.

Trust and transparency are fundamental to the recruiter/candidate and the recruiter/client relationship. “Transparency and trust coincide. Trust is key to any relationship. If you don’t have trust, it’s really hard to build anything else,” said Boyles. From the initial description, it is up to the recruiter to clarify what skills the company needs; understand the absolute ‘must haves’ and ‘nice to haves.’ Knowing these elements will clearly define the role. “As a staffing firm, we need to do the right things to make sure we understand the [job] requirements,” said Rainier.

Catapult Solutions Group focuses on relationships and the people. These two elements are what remains the core of successful recruiting. To get your resume to a connected Catapult Recruiter, visit their website at catapultsg.com.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More